The authors have indicated no significant interest with commercial supporters.
Basic Pharmacology of Topical Imiquimod, 5-Fluorouracil, and Diclofenac for the Dermatologic Surgeon
Article first published online: 14 OCT 2011
© 2011 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.
Volume 38, Issue 1, pages 97–103, January 2012
How to Cite
Desai, T., Chen, C. L., Desai, A. and Kirby, W. (2012), Basic Pharmacology of Topical Imiquimod, 5-Fluorouracil, and Diclofenac for the Dermatologic Surgeon. Dermatologic Surgery, 38: 97–103. doi: 10.1111/j.1524-4725.2011.02194.x
- Issue published online: 5 JAN 2012
- Article first published online: 14 OCT 2011
Ultraviolet radiation (UVR) contributes to the vast majority of nonmelanoma skin cancer (NMSC). As the incidence of NMSC continues to rise, topical therapies will be used with increasing frequency. Topical therapies may benefit high-risk surgical candidates as an alternative treatment modality and may improve overall cosmesis. The most commonly employed topical therapies are imiquimod, 5-fluorouracil (5-FU), and diclofenac.
To review the detailed mechanism of action and side-effect profiles of each topical therapy used to treat NMSC and to explore newly discovered actions. Uncommon adverse events are also presented.
Materials and Methods
An extensive literature search was performed to describe the pharmacologic actions of imiquimod, 5-FU, and diclofenac.
A keen understanding of the pharmacologic concepts of these topical therapies may aid the dermatologic surgeon in making sound choices before, during, and after surgery.